A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity

NCTNCT07508020Other idNN9490-8151Other idU1111-1319-9246Other id2025-521393-34Other id2025

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Recruiting
Phase: Phase 1
Enrollment: 120 participants (estimated)
Sponsor: Novo Nordisk A/S · Industry
Design: Randomized · Quadruple masking
Countries: 1 country
Germany
Start: 30 Mar 2026
Primary completion: 19 Jan 2028 (estimated)
Completion: 22 Jan 2028 (estimated)
First posted: 2 Apr 2026
Last update posted: 27 Apr 2026
Conditions: Obesity

Timeline

1 trial · 1 ongoing

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2026202720282029

Ph 1
A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity
NCT07508020
30 Mar 2026 to est. 22 Jan 2028

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this clinical study is to look at if/how much NNC0487-0111 affects food intake, appetite and metabolism in participants with obesity when compared to placebo. There are 2 study treatments in this study. Participants will inject the study treatment under the skin of your stomach once a week. Participants will get either NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants will get is decided by chance.

Interventions

NNC0487-0111Drug
Placebo (matched to NNC0487-0111)Drug

Arms2

Experimental
NNC0487-0111
Participants will be randomized to receive 1 of the different dose levels of NNC0487-0111 subcutaneously once weekly.
Placebo comparator
Placebo
Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly.

Primary outcomes3

Outcomes the sponsor listed as primary.

Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126
Time frame · From Baseline to Day 126
Registry description
Measured as percentage change of energy.
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182
Time frame · From Baseline to Day 182
Registry description
Measured as percentage change of energy.
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238
Time frame · From Baseline to Day 238
Registry description
Measured as percentage change of energy.

Secondary outcomes(17)

Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126
Time frame · From Baseline to Day 126
Registry description
Measured as kilojoules (kJ).
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182
Time frame · From Baseline to Day 182
Registry description
Measured as kJ.
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238
Time frame · From Baseline to Day 238
Registry description
Measured as kJ.
Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 126
Time frame · From Baseline to Day 126
Registry description
Measured as grams.
Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 182
Time frame · From Baseline to Day 182
Registry description
Measured as grams.
Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 238
Time frame · From Baseline to Day 238
Registry description
Measured as grams.
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 378
Time frame · From Baseline to Day 378
Registry description
Measured as percentage change of energy.
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box at Day 378
Time frame · From Baseline to Day 378
Registry description
Measured as kJ.
Change from baseline in total amount of food consumed during ad libitum breakfast, lunch, evening meal and snack box to Day 378
Time frame · From Baseline to Day 378
Registry description
Measured as grams.
Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 126
Time frame · From Baseline to Day 126
Registry description
Measured as kJ.
Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 182
Time frame · From Baseline to Day 182
Registry description
Measured as kJ.
Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 238
Time frame · From Baseline to Day 238
Registry description
Measured as kJ.
Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 378
Time frame · From Baseline to Day 378
Registry description
Measured as kJ.
Relative change from Day 19 in body weight to Day 131
Time frame · From Day 19 to Day 131
Registry description
Measured as percentage change of body weight.
Relative change from Day 19 in body weight to Day 187
Time frame · From Day 19 to Day 187
Registry description
Measured as percentage change of body weight.
Relative change from Day 19 in body weight to Day 243
Time frame · From Day 19 to Day 243
Registry description
Measured as percentage change of body weight.
Relative change from Day 19 in body weight to Day 383
Time frame · From Day 19 to Day 383
Registry description
Measured as percentage change of body weight.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex: All
Age: from 18 Years up to 64 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Key Inclusion Criteria: * Male or female (sex at birth). * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. * Overweight should be due to excess adipose tissue, as judged by the investigator. Key Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method. * History of type 1 or type 2 diabetes mellitus. * Glycated hemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole \[mmol/mol\]) at screening. * Use of incretin or amylin-based therapies prior to screening or previous discontinuation of long-term incretin and/or amylin-based therapy due to tolerability issues. * Any clinically significant body weight change (≥5 % self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening. * Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions.

PepBank is a research reference. Talk to a doctor before you use any peptide.